

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

BSE Limited 1st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u> Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u> Kind Attn.: Famroze Pochara Asst. Vice President
Date: December 3, 2016	
Re.: Press Release	

Dear Sir / Madam,

We enclose herewith a copy of press release dated December 3, 2016, titled "Zydus Announces Settlement of a DELZICOL® (mesalamine) Patent Litigation. The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For, Cadila Healthcare Limited



Upen H. Shah
Company Secretary



Encl.: As above

Zydus Announces Settlement of a DELZICOL® (mesalamine) Patent Litigation

Ahmedabad, Dec. 3, 2016

Zydus Cadila, an innovation-driven global pharmaceutical company, announced that the patent litigation relating to Allergan's DELZICOL® (mesalamine) has been settled. As a result of the settlement, and if approved by FDA, its US subsidiary, Zydus Pharmaceuticals (USA) Inc., will be able to market its generic version of DELZICOL® in the United States beginning on March 1, 2020, or earlier under certain circumstances.

###